COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases

Launched by AMSTERDAM UMC, LOCATION VUMC · Dec 14, 2023

Keywords

ClinConnect Summary

The COLDFIRE-III Trial is a clinical study that aims to compare two treatment methods for patients with colorectal cancer that has spread to the liver and cannot be surgically removed. The treatments being studied are irreversible electroporation (IRE), which uses electrical pulses to destroy cancer cells, and stereotactic body radiotherapy (SBRT), a form of targeted radiation therapy. The main goal of the trial is to see which method does a better job of controlling the cancer in the liver over a two-year period.

To participate in this trial, patients should be adults over 18 years old who have a confirmed diagnosis of colorectal cancer and 1 to 3 visible liver tumors that are too close to blood vessels or bile ducts for surgery. They should also have good overall health and organ function. Participants will receive either IRE or SBRT and will be monitored to assess how well the treatments are working. This trial is currently looking for volunteers, so if you or someone you know might be eligible, it's a good idea to discuss it with a healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological documentation of primary colorectal tumor is available;
• • 1-3 CRLM visible on ceCT and/or MRI, size 0-5 cm and not eligible for resection or thermal ablation due to location close to a vessel or bile duct;
• • Additional CRLM are allowed if considered either resectable or ablatable with a maximum of 10 CRLM. In patients with extrahepatic disease, a maximum of 5 additional CRLM is allowed;
• • No or limited extrahepatic disease (1 extrahepatic lesion is allowed, with some exclusions mentioned in the exclusion criteria);
• • Prior focal liver treatment is allowed;
• • Subjects should preferably be treated with neo-adjuvant systemic therapy;
• • Subjects with recurrent (either local or distant-hepatic) CRLM after previous focal treatment who are unsuitable for (further) systemic therapy (further downsizing or conversion to resectable disease improbable);
• • Adequate bone marrow, liver and renal function as assessed by laboratory requirements to be conducted within 7 days prior to definite inclusion;
• • ASA classification 0 - 3;
• • Age \>18 years;
• • Written informed consent;
• Exclusion Criteria:
• • Radical treatment unfeasible or unsafe (e.g. insufficient FLR);
• • \>10 CRLM; \>5 CRLM when extra-hepatic disease is present;
• • Positive para-aortal lymph nodes, celiac lymph nodes, adrenal metastases, pleural carcinomatosis or peritoneal carcinomatosis;
• • Subjects who have progressive disease after neo-adjuvant systemic therapy;
• • History of epilepsy;
• * History of cardiac disease:
• • Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen;
• • Compromised liver function (e.g. signs of portal hypertension, INR \> 1,5 without use of anticoagulants, ascites);
• • Pregnant or breast-feeding subjects;
• • Immunotherapy ≤ 2 weeks prior to the procedure;
• • Chemotherapy and/or targeted therapy ≤ 2 weeks prior to the procedure;
• • Severe allergy to contrast media not controlled with premedication;
• • Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study.